Joseph J. Hlavka
Corporate Officer/Principal bei Tetragenex Pharmaceuticals, Inc.
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| David Abel | M | 79 |
Tetragenex Pharmaceuticals, Inc.
 Tetragenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tetragenex Pharmaceuticals, Inc. operates as a biotechnology company. It develops and commercializes proprietary pharmaceutical products for use in treatment resistant depression and other central nervous system diseases in the United States. The firm's principal product is Nemifitide, an antidepressant compound, which is in Phase II clinical trials for the treatment of depression, anxiety, and other central nervous system disorders. The company was founded in 1989 and is headquartered in Syosset, NY. | 30 Jahre |
| Martin F. Schacker | M | 65 |
Tetragenex Pharmaceuticals, Inc.
Tetragenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tetragenex Pharmaceuticals, Inc. operates as a biotechnology company. It develops and commercializes proprietary pharmaceutical products for use in treatment resistant depression and other central nervous system diseases in the United States. The firm's principal product is Nemifitide, an antidepressant compound, which is in Phase II clinical trials for the treatment of depression, anxiety, and other central nervous system disorders. The company was founded in 1989 and is headquartered in Syosset, NY. | 30 Jahre |
| Aaron S. Cohen | M | 87 |
Tetragenex Pharmaceuticals, Inc.
Tetragenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tetragenex Pharmaceuticals, Inc. operates as a biotechnology company. It develops and commercializes proprietary pharmaceutical products for use in treatment resistant depression and other central nervous system diseases in the United States. The firm's principal product is Nemifitide, an antidepressant compound, which is in Phase II clinical trials for the treatment of depression, anxiety, and other central nervous system disorders. The company was founded in 1989 and is headquartered in Syosset, NY. | 23 Jahre |
| William T. Comer | M | 85 |
Tetragenex Pharmaceuticals, Inc.
Tetragenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tetragenex Pharmaceuticals, Inc. operates as a biotechnology company. It develops and commercializes proprietary pharmaceutical products for use in treatment resistant depression and other central nervous system diseases in the United States. The firm's principal product is Nemifitide, an antidepressant compound, which is in Phase II clinical trials for the treatment of depression, anxiety, and other central nervous system disorders. The company was founded in 1989 and is headquartered in Syosset, NY. | 23 Jahre |
| Bruce J. Bergman | M | 76 |
Tetragenex Pharmaceuticals, Inc.
Tetragenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tetragenex Pharmaceuticals, Inc. operates as a biotechnology company. It develops and commercializes proprietary pharmaceutical products for use in treatment resistant depression and other central nervous system diseases in the United States. The firm's principal product is Nemifitide, an antidepressant compound, which is in Phase II clinical trials for the treatment of depression, anxiety, and other central nervous system disorders. The company was founded in 1989 and is headquartered in Syosset, NY. | 30 Jahre |
| Alf E. F. Akerman | M | 58 |
Tetragenex Pharmaceuticals, Inc.
Tetragenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tetragenex Pharmaceuticals, Inc. operates as a biotechnology company. It develops and commercializes proprietary pharmaceutical products for use in treatment resistant depression and other central nervous system diseases in the United States. The firm's principal product is Nemifitide, an antidepressant compound, which is in Phase II clinical trials for the treatment of depression, anxiety, and other central nervous system disorders. The company was founded in 1989 and is headquartered in Syosset, NY. | 25 Jahre |
| Kenneth Cartwright | M | 86 |
Tetragenex Pharmaceuticals, Inc.
Tetragenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tetragenex Pharmaceuticals, Inc. operates as a biotechnology company. It develops and commercializes proprietary pharmaceutical products for use in treatment resistant depression and other central nervous system diseases in the United States. The firm's principal product is Nemifitide, an antidepressant compound, which is in Phase II clinical trials for the treatment of depression, anxiety, and other central nervous system disorders. The company was founded in 1989 and is headquartered in Syosset, NY. | 35 Jahre |
| Robert Peter Budetti | M | 79 |
Tetragenex Pharmaceuticals, Inc.
Tetragenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tetragenex Pharmaceuticals, Inc. operates as a biotechnology company. It develops and commercializes proprietary pharmaceutical products for use in treatment resistant depression and other central nervous system diseases in the United States. The firm's principal product is Nemifitide, an antidepressant compound, which is in Phase II clinical trials for the treatment of depression, anxiety, and other central nervous system disorders. The company was founded in 1989 and is headquartered in Syosset, NY. | 25 Jahre |
| Richard J. Ablin | M | - |
Tetragenex Pharmaceuticals, Inc.
Tetragenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tetragenex Pharmaceuticals, Inc. operates as a biotechnology company. It develops and commercializes proprietary pharmaceutical products for use in treatment resistant depression and other central nervous system diseases in the United States. The firm's principal product is Nemifitide, an antidepressant compound, which is in Phase II clinical trials for the treatment of depression, anxiety, and other central nervous system disorders. The company was founded in 1989 and is headquartered in Syosset, NY. | 33 Jahre |
| Gabriela Nicolau | M | - |
Tetragenex Pharmaceuticals, Inc.
Tetragenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tetragenex Pharmaceuticals, Inc. operates as a biotechnology company. It develops and commercializes proprietary pharmaceutical products for use in treatment resistant depression and other central nervous system diseases in the United States. The firm's principal product is Nemifitide, an antidepressant compound, which is in Phase II clinical trials for the treatment of depression, anxiety, and other central nervous system disorders. The company was founded in 1989 and is headquartered in Syosset, NY. | 29 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Dov Elefant | M | 56 |
Tetragenex Pharmaceuticals, Inc.
Tetragenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tetragenex Pharmaceuticals, Inc. operates as a biotechnology company. It develops and commercializes proprietary pharmaceutical products for use in treatment resistant depression and other central nervous system diseases in the United States. The firm's principal product is Nemifitide, an antidepressant compound, which is in Phase II clinical trials for the treatment of depression, anxiety, and other central nervous system disorders. The company was founded in 1989 and is headquartered in Syosset, NY. | 8 Jahre |
| Neil Martucci | M | 49 |
Tetragenex Pharmaceuticals, Inc.
Tetragenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tetragenex Pharmaceuticals, Inc. operates as a biotechnology company. It develops and commercializes proprietary pharmaceutical products for use in treatment resistant depression and other central nervous system diseases in the United States. The firm's principal product is Nemifitide, an antidepressant compound, which is in Phase II clinical trials for the treatment of depression, anxiety, and other central nervous system disorders. The company was founded in 1989 and is headquartered in Syosset, NY. | 9 Jahre |
| Irwin Jacobs | M | 90 |
Massachusetts Institute of Technology
| 3 Jahre |
| John Sununu | M | 85 |
Massachusetts Institute of Technology
| 4 Jahre |
| Tom Cantwell | M | 96 |
Massachusetts Institute of Technology
| 3 Jahre |
| John A. Lordi | M | - |
Massachusetts Institute of Technology
| 4 Jahre |
| Allen Gersho | M | - |
Massachusetts Institute of Technology
| 4 Jahre |
| Roger S. Borovoy | M | - |
Massachusetts Institute of Technology
| 4 Jahre |
| Harold Weiss | M | - |
Massachusetts Institute of Technology
| 4 Jahre |
| Charles W. Johnson | M | - |
Massachusetts Institute of Technology
| 3 Jahre |
| William R. Oakes | M | - |
Massachusetts Institute of Technology
| 4 Jahre |
| Donald Arthur Norman | M | 88 |
Massachusetts Institute of Technology
| 4 Jahre |
| Alan V. Oppenheim | M | - |
Massachusetts Institute of Technology
| 4 Jahre |
| Paul H. Fricke | M | - |
Massachusetts Institute of Technology
| 4 Jahre |
| Kent Kresa | M | 86 |
Massachusetts Institute of Technology
| 4 Jahre |
| John P. Feighner | M | - |
Tetragenex Pharmaceuticals, Inc.
Tetragenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tetragenex Pharmaceuticals, Inc. operates as a biotechnology company. It develops and commercializes proprietary pharmaceutical products for use in treatment resistant depression and other central nervous system diseases in the United States. The firm's principal product is Nemifitide, an antidepressant compound, which is in Phase II clinical trials for the treatment of depression, anxiety, and other central nervous system disorders. The company was founded in 1989 and is headquartered in Syosset, NY. | 7 Jahre |
| Patrick Joseph McGovern | M | 86 |
Massachusetts Institute of Technology
| 4 Jahre |
| Sheila E. Widnall | M | 85 |
Massachusetts Institute of Technology
| 4 Jahre |
| Alexander MacLachlan | M | 91 |
Massachusetts Institute of Technology
| 2 Jahre |
| James Alan Abrahamson | M | 90 |
Massachusetts Institute of Technology
| 4 Jahre |
| Nam Pyo Suh | M | 88 |
Massachusetts Institute of Technology
| 4 Jahre |
| Thomas V. Buffett | M | - |
Massachusetts Institute of Technology
| 4 Jahre |
| Jim Forese | M | 86 |
Massachusetts Institute of Technology
| 4 Jahre |
| Bob E. Larson | M | 85 |
Massachusetts Institute of Technology
| 4 Jahre |
| John Deutch | M | 85 |
Massachusetts Institute of Technology
| 4 Jahre |
| Ira J. Jaffe | M | - |
Massachusetts Institute of Technology
| 4 Jahre |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Vereinigte Staaten | 36 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Joseph J. Hlavka
- Persönliches Netzwerk
